Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence
Executive Summary
The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.
You may also be interested in...
Synthetic Biologics Thinks Statins May Get At Root Of IBS-Constipation
Biotech set to develop patented special-release statin formulation for a new approach to constipation-predominant irritable bowel syndrome – methane gas. The same research also underpins development of Salix’ Xifaxan for diarrhea-predominant IBS.
Ironwood/Forest Hoping To Change The Conversation About Constipation
The partners began a DTC campaign to promote their constipation drug and ease the conversation between physicians and patients about the often embarrassing condition.
Ironwood/Forest Hoping To Change The Conversation About Constipation
The partners began a DTC campaign to promote their constipation drug and ease the conversation between physicians and patients about the often embarrassing condition.